Sequential administration of interferon γ and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial

2000 ◽  
Vol 49 (7) ◽  
pp. 395-400 ◽  
Author(s):  
Manuela Schmidinger ◽  
Günther G. Steger ◽  
Catharina Wenzel ◽  
Gottfried J. Locker ◽  
Thomas Brodowicz ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Interferon Γ ◽  
Sequential Administration

Sequential Administration of Interferon-γ, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial

2001 ◽  
Vol 24 (3) ◽  
pp. 257-262 ◽  
Author(s):  
Manuela Schmidinger ◽  
Guenther Steger ◽  
Catharina Wenzel ◽  
Gottfried J. Locker ◽  
Alexandra C. Budinsky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Interferon Γ ◽  
Gm Csf ◽  
Sequential Administration

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.

1998 ◽  
Vol 16 (8) ◽  
pp. 2728-2732 ◽  
Author(s):  
A Ravaud ◽  
B Audhuy ◽  
F Gomez ◽  
B Escudier ◽  
T Lesimple ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Interferon Alfa

PURPOSE A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS One hundred eleven patients were included. Patients received subcutaneous IL-2 9 x 10(6) IU daily for 6 days and IFNalpha 6 x 10(6) IU on days 1, 3, and 5 every other week for 8 weeks. 5-FU was administered through a continuous infusion at 600 mg/m2 for 5 consecutive days for 1 week every 4 weeks. RESULTS The response rate was 1.8% (95% confidence interval [CI], 0% to 4.3%) with only two partial responses (PRs). Toxicity was moderate with 3.6% grade 4 events and two deaths related to treatment. CONCLUSION This regimen of IL-2, IFNalpha, and 5-FU in patients with metastatic renal cell carcinoma was ineffective. The results raise the question of the dose and schedule of subcutaneous cytokines that must be used in metastatic renal carcinoma.

Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

Cancer ◽  
1997 ◽  
Vol 80 (11) ◽  
pp. 2128-2132 ◽  
Author(s):  
Julie A. Ellerhorst ◽  
Avishay Sella ◽  
Robert J. Amato ◽  
Shi-Ming Tu ◽  
Randall E. Millikan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2
Sign in / Sign up

Export Citation Format

Share Document